Abstract
Chemotherapy with TAS-102 with bevacizumab (Bmab) is a new treatment for metastatic colorectal cancer. A 67-year-old male patient with synchronous multiple liver metastases was treated with TAS-102 with Bmab as a fifth-line chemotherapy. It was demonstrated that liver metastases decreased in size by 13% by computed tomography (CT) after 3 months of TAS-102 with Bmab therapy. The Grade 3 or worst adverse event that was experienced was neutropenia. The patient was able to continue treatment with TAS-102 with Bmab for 6 months. TAS-102 with Bmab treatment was safety and efficacious as a late-line chemotherapy treatment for metastatic colorectal cancer.
| Original language | English |
|---|---|
| Pages (from-to) | 649-651 |
| Number of pages | 3 |
| Journal | Japanese Journal of Cancer and Chemotherapy |
| Volume | 45 |
| Issue number | 4 |
| Publication status | Published - 04-2018 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
All Science Journal Classification (ASJC) codes
- Oncology
- Cancer Research
Fingerprint
Dive into the research topics of 'Safety and efficacy of TAS-102 with bevacizumab for the treatment of unresectable metastatic colorectal cancer-a case report'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver